Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-15
2008-07-15
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S395000, C546S273700, C548S307100
Reexamination Certificate
active
07399772
ABSTRACT:
The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical composition consisting of a proton pump inhibitor and at least one buffering agent. Also provided is a pharmaceutical composition further comprising a parietal cell activator, an anti-foaming agent, a flavoring agent and combinations thereof; a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical composition; and, a kit for the preparation of a liquid oral pharmaceutical composition. Dosage forms include: liquid, powder, tablet, capsule, effervescent powder, effervescent tablet, pellets, and granules.
REFERENCES:
patent: 4252790 (1981-02-01), Higuchi
patent: 4689333 (1987-08-01), Nohara et al.
patent: 4990535 (1991-02-01), Cho et al.
patent: 5041442 (1991-08-01), Romero et al.
patent: 5093132 (1992-03-01), Makino et al.
patent: 5294439 (1994-03-01), Yamasaka et al.
patent: 5447918 (1995-09-01), McCullough
patent: 5703097 (1997-12-01), Kim et al.
patent: 5762962 (1998-06-01), Georgiades et al.
patent: 5840737 (1998-11-01), Phillips
patent: 5876759 (1999-03-01), Gowan
patent: 6090827 (2000-07-01), Erickson et al.
patent: 6183776 (2001-02-01), Depui
patent: 6248363 (2001-06-01), Patel et al.
patent: 6262085 (2001-07-01), Whittle et al.
patent: 6262086 (2001-07-01), Whittle et al.
patent: 6268385 (2001-07-01), Whittle et al.
patent: 6280773 (2001-08-01), Cho et al.
patent: 6328993 (2001-12-01), Linder et al.
patent: 6489346 (2002-12-01), Phillips
patent: 6569453 (2003-05-01), Linder et al.
patent: 6608091 (2003-08-01), Whittall et al.
patent: 6608092 (2003-08-01), Fujishima et al.
patent: 6608210 (2003-08-01), Naka et al.
patent: 6623759 (2003-09-01), Heese et al.
patent: 6645988 (2003-11-01), Phillips
patent: 6649609 (2003-11-01), Teuber et al.
patent: 6664276 (2003-12-01), Fujishima et al.
patent: 6677455 (2004-01-01), Kronstrom et al.
patent: 6699885 (2004-03-01), Phillips
patent: 6749867 (2004-06-01), Robinson et al.
patent: 6780882 (2004-08-01), Phillips
patent: 2001/0053387 (2001-12-01), Hamied et al.
patent: 2002/0192299 (2002-12-01), Taneja et al.
patent: 2003/0144306 (2003-07-01), Phillips
patent: 2003/0181457 (2003-09-01), Orme et al.
patent: 2003/0199580 (2003-10-01), Kishi et al.
patent: 2003/0211147 (2003-11-01), Cullen et al.
patent: 2003/0215527 (2003-11-01), Phillips
patent: 2003/0225136 (2003-12-01), Whittle et al.
patent: 2004/0010151 (2004-01-01), Finkelstein et al.
patent: 2004/0048896 (2004-03-01), Phillips
patent: 2004/0058018 (2004-03-01), Phillips
patent: 2005/0037070 (2005-02-01), Hall et al.
patent: 197 52 843 (1999-07-01), None
patent: 480691 (1992-04-01), None
patent: 0584588 (1993-08-01), None
patent: 0587659 (1994-03-01), None
patent: 0670160 (1999-07-01), None
patent: 1043977 (2003-10-01), None
patent: 1375497 (2004-01-01), None
patent: 46 009581 (1971-11-01), None
patent: 52 102416 (1977-08-01), None
patent: 51-17268 (1993-05-01), None
patent: 05-255088 (1993-10-01), None
patent: 2000355540 (2000-12-01), None
patent: WO 9003184 (1990-04-01), None
patent: WO 9009175 (1990-08-01), None
patent: WO 9221331 (1992-12-01), None
patent: WO 9313138 (1995-03-01), None
patent: WO 9532959 (1995-12-01), None
patent: WO 9601622 (1996-01-01), None
patent: WO 9702020 (1997-01-01), None
patent: WO 9702021 (1997-01-01), None
patent: WO 9936060 (1999-07-01), None
patent: WO 0001372 (2000-01-01), None
patent: WO 0113919 (2001-03-01), None
patent: WO 0134573 (2001-05-01), None
patent: WO 0151050 (2001-07-01), None
patent: WO 03009846 (2003-02-01), None
patent: WO 03017980 (2003-03-01), None
patent: WO 03061584 (2003-07-01), None
patent: WO 03063927 (2003-08-01), None
Antiacid bottle instruction.
Borella et al. “Gastric antisecretory and . . . ” CA 111:50223 (1989).
Tanaka et al. “Pathogenesis of the earliest . . . ” CA 112:30369 (1990).
Tabata et al. “Stabilization of a new . . . ” CA 117:118333 (1992).
Tabata et al. “Stabilization of a new antiulcer . . . ” Drug development and Ind. Pharm. 18, 1437-47 (1992).
Trilateral project B3b, Reach trought claims, p. 1-28 (2001).
Borella et al. Gastric antisecretory . . .1Ca 111:50223 (1989).
Ekpe et al. “Effect of various salts on . . . ” CA 131:341883 (1999).
DiGiacinto et al. “Stability of suspension . . . ” CA 133:22290 (2000).
RN 73590-58-6.
Tonini et al. “Clinical Pharmacology and safety . . . ” digest Liver disease 33 p. 600-606 (2001).
“Buffered and Isotonic Solutions”,Physical Pharmacy, Chapter 8, pp. 169-189.
Aihara, Takeshi et al., “Pharmacological Control of Gastric Acid Secretion for the Treatment of Acid-related Peptic Disease: Past, Present, and Future”,Pharmacology&Therapeutics 98, pp. 109-127 (2003).
Andersson, T., et al., “Pharmacokinetics of [14C]Omeprazole in Patients with Liver Cirrhosis”,Clin Pharmacokinet., vol. 24, No. 1, pp. 71-78 (1993).
Ballard, E., et al., “Bioequivalence Between Lansoprazole Sachet for Suspension and intact Capsule,”Gastroenterology, vol. 120 (No. %, Suppl. 1), p. A-245 (2001).
Beekman, S. M., “Preparation and Properties of New Gastric Antacids I”,J. Pharm Assoc, vol. 49, pp. 191-200, (1960).
Blum, A., “Therapeutic Approach to Ulcer Healing,”The American Journal of Medicine, vol. 79 (Suppl. 2C), pp. 8-14 (Aug. 30, 1985).
Ferron et al., “Oral Bioavailability of Pantoprazole Suspended in Sodium Bicarbonate Solution”,Am J Health-Syst Pharm, vol. 60, pp. 1324-1328 (Jul. 1, 2003).
Fuchs, C., “Antacids, Their Function, Formulation and Evaluation”,Drug and Cosmetic Industry, vol. 64, pp. 692-773, (1949).
Kromer, et al., “Differences in pH-Dependent Activition Rate of Substituted Benzimidazoles and Biological in vitro Correlates”,Pharmacology, vol. 56, pp. 57-70, (1998).
Ley, B. et al., “Bioavailability of a Crushed Pantoprazole Tablet after Buffering with Sodium Hydrogencarbonate or Magaldrate Relative to the Intact Enteric Coated Pantoprazole Tablet”,Methods and Findings in Experimental and Clinical Pharmacolgy, vol. 23, pp. 41-45 (2001).
“Supplemental Information Disclosure Statement” as filed with U.S. Patent and Trademark Office on Dec. 21, 2001 for U.S. Appl. No. 09/481,207 (U.S. Patent 6,489,346.
Meiners, et al., “Evaluation of Various Techniques to Monitor Intragastric pH”,Arch. Surg., vol. 117, No. 3, pp. 288-291 (1982).
Phillips, J., et al., “A Randomized, Pharmacokinetic and Pharmacodynamic, Cross-over Study of Duodenal of Jejunal Administration Compared to Nasogastric Administration of Omeprazole Suspension in Patients at Risk for Stress Ulcers”,The American Journal of Gastroenterology, vol. 96, No. 2 (2001).
Phillips, J., Presentation: “Problems with Administering Granules”,Overview of Omeprazole Suspension, (1999/2000).
Phillips, Project #5122: “Simplified Omeprazole Solution (S.O.S.)—Pharmacokinetic/Pharmacodynamic Study in Patients at Risk for Stress Related Mucosal Damage (SRMD)” (Approved Apr. 28, 1994).
Pilbrant, “Principles for Development of Antacids”,Scand. J. Gastroenterol Suppl., vol. 75, pp. 32-36 (1982).
Rohan, E., “Nasogastric Administration of Omeprazole”,The Australian Journal of Hospital Pharmacy, vol. 28, No. 3, pp. 174-176 (1998).
Schepp, “Stress Ulcer Prophylaxis: Still a Valid Option in the 1990s?”,Digestion, vol. 54, No. 4, pp. 189-199 (1993).
Tytgat, G., “Drug Therapy of Reflux Oesophagitis: An Update,”Scand J. Gastroenterol., vol. 24 (Suppl.168), pp. 38-49 91989).
Oct. 18, 2007, Answer and Counterclaim filed by Par Pharmaceutical.
Nov. 9, 2007, Reply to Counterclaims filed by Santarus and The Curators of the University of Missouri.
Jan. 30, 2008 Amended Answer and Counterclaims filed by Par Pharmaceutical, Case No. 07-827-GMS (D. Del.).
Feb. 22, 2008 Plaintiff's Motion
Chang Celia
Curators of the University of Missouri
Mayer Brown LLP
LandOfFree
Substituted benzimidazole dosage forms and method of using same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted benzimidazole dosage forms and method of using same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted benzimidazole dosage forms and method of using same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2788584